Literature DB >> 24442790

In vivo characterization and numerical simulation of prostate properties for non-thermal irreversible electroporation ablation.

Robert E Neal1, Jeremy L Millar, Helen Kavnoudias, Peter Royce, Franklin Rosenfeldt, Alan Pham, Ryan Smith, Rafael V Davalos, Kenneth R Thomson.   

Abstract

BACKGROUND: Irreversible electroporation (IRE) delivers brief electric pulses to attain non-thermal focal ablation that spares vasculature and other sensitive systems. It is a promising prostate cancer treatment due to sparing of the tissues associated with morbidity risk from conventional therapies. IRE effects depend on electric field strength and tissue properties. These characteristics are organ-dependent, affecting IRE treatment outcomes. This study characterizes the relevant properties to improve treatment planning and outcome predictions for IRE prostate cancer treatment.
METHODS: Clinically relevant IRE pulse protocols were delivered to a healthy canine and two human cancerous prostates while measuring electrical parameters to determine tissue characteristics for predictive treatment simulations. Prostates were resected 5 hr, 3 weeks, and 4 weeks post-IRE. Lesions were correlated with numerical simulations to determine an effective prostate lethal IRE electric field threshold.
RESULTS: Lesions were produced in all subjects. Tissue electrical conductivity increased from 0.284 to 0.927 S/m due to IRE pulses. Numerical simulations show an average effective prostate electric field threshold of 1072 ± 119 V/cm, significantly higher than previously characterized tissues. Histological findings in the human cases show instances of complete tissue necrosis centrally with variable tissue effects beyond the margin.
CONCLUSIONS: Preliminary experimental IRE trials safely ablated healthy canine and cancerous human prostates, as examined in the short- and medium-term. IRE-relevant prostate properties are now experimentally and numerically defined. Importantly, the electric field required to kill healthy prostate tissue is substantially higher than previously characterized tissues. These findings can be applied to optimize IRE prostate cancer treatment protocols.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  IRE; finite element modeling; preclinical trials; prostate cancer; targeted therapy; translational research

Mesh:

Year:  2014        PMID: 24442790     DOI: 10.1002/pros.22760

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  36 in total

1.  Enhancing Irreversible Electroporation by Manipulating Cellular Biophysics with a Molecular Adjuvant.

Authors:  Jill W Ivey; Eduardo L Latouche; Megan L Richards; Glenn J Lesser; Waldemar Debinski; Rafael V Davalos; Scott S Verbridge
Journal:  Biophys J       Date:  2017-07-25       Impact factor: 4.033

Review 2.  Technical and practical considerations for device selection in locoregional ablative therapy.

Authors:  Sean P Zivin; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

Review 3.  Irreversible Electroporation for the Ablation of Prostate Cancer.

Authors:  Andreas Karagiannis; John Varkarakis
Journal:  Curr Urol Rep       Date:  2019-09-02       Impact factor: 3.092

Review 4.  Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment.

Authors:  Jill W Ivey; Mohammad Bonakdar; Akanksha Kanitkar; Rafael V Davalos; Scott S Verbridge
Journal:  Cancer Lett       Date:  2015-12-24       Impact factor: 8.679

5.  Irreversible electroporation for the treatment of localized prostate cancer: a summary of imaging findings and treatment feedback.

Authors:  Matthijs J Scheltema; Arnoud W Postema; Daniel M de Bruin; Mara Buijs; Marc R Engelbrecht; M Pilar Laguna; Hessel Wijkstra; Theo M de Reijke; Jean J M C H de la Rosette
Journal:  Diagn Interv Radiol       Date:  2017 Sep-Oct       Impact factor: 2.630

Review 6.  [Irreversible electroporation. Current value for focal treatment of prostate cancer].

Authors:  J J Wendler; R Ganzer; B Hadaschik; A Blana; T Henkel; K U Köhrmann; S Machtens; A Roosen; G Salomon; L Sentker; U Witzsch; H P Schlemmer; D Baumunk; J Köllermann; M Schostak; U B Liehr
Journal:  Urologe A       Date:  2015-06       Impact factor: 0.639

7.  Electrical resistance of human soft tissue sarcomas: an ex vivo study on surgical specimens.

Authors:  L G Campana; M Cesari; F Dughiero; M Forzan; M Rastrelli; C R Rossi; E Sieni; A L Tosi
Journal:  Med Biol Eng Comput       Date:  2015-09-01       Impact factor: 2.602

8.  Mathematical Models Describing Chinese Hamster Ovary Cell Death Due to Electroporation In Vitro.

Authors:  Janja Dermol; Damijan Miklavčič
Journal:  J Membr Biol       Date:  2015-07-30       Impact factor: 1.843

Review 9.  Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage.

Authors:  J J Wendler; R Ganzer; B Hadaschik; A Blana; T Henkel; K U Köhrmann; S Machtens; A Roosen; G Salomon; L Sentker; U Witzsch; H P Schlemmer; D Baumunk; J Köllermann; M Schostak; U B Liehr
Journal:  World J Urol       Date:  2016-05-04       Impact factor: 4.226

10.  Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control.

Authors:  F Ting; M Tran; M Böhm; A Siriwardana; P J Van Leeuwen; A M Haynes; W Delprado; R Shnier; P D Stricker
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-10-13       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.